For pwPMS, the following variables were registered at baseline: date of birth, date of MS diagnosis, sex, baseline age and disease duration, current disease-modifying therapy (DMT), PRO measures, and date of completion.
For pwRMS, the same variables were recorded at baseline plus cerebrospinal fluid (CSF) neurofilament light chain protein (NFL) and chitinase3 like-1 (CHI3L1) levels, and CSF oligoclonal G and M bands (for Methods22 (link)). CSF biomarkers were available in 50 pwRMS (58.1%). During the 2-year study period and every three to six months, serum NFL – measured with SiMoA SR-X according to manufacturer’s instructions [Quanterix Corporation, Lexington, MA 02,421, USA]—EDSS, symbol digit modality test (SDMT)40 (link), 9-hole peg test (9-HPT)41 (link), and timed 25-foot walk test (T25-FW) were registered41 (link).
For pwRMS, the same variables were recorded at baseline plus cerebrospinal fluid (CSF) neurofilament light chain protein (NFL) and chitinase3 like-1 (CHI3L1) levels, and CSF oligoclonal G and M bands (for Methods22 (link)). CSF biomarkers were available in 50 pwRMS (58.1%). During the 2-year study period and every three to six months, serum NFL – measured with SiMoA SR-X according to manufacturer’s instructions [Quanterix Corporation, Lexington, MA 02,421, USA]—EDSS, symbol digit modality test (SDMT)40 (link), 9-hole peg test (9-HPT)41 (link), and timed 25-foot walk test (T25-FW) were registered41 (link).
Free full text: Click here
